Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
tumor lysis syndrome
MeSH D015275 - tumor lysis syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D008232:
Lymphoproliferative disorders
2 Companies
2 Drugs
$
Success rate
D015275:
Tumor lysis syndrome
1 Company
1 Drug
$
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Sanofi
Rasburicase
Elitek
2002-07-12
Rasburicase
Fasturtec
2001-02-23
Clinical Trials
Historical Success Rate
Phase 1
100
%
2/2
Phase 2
100
%
2/2
Phase 3
40
%
2/5
Approved:
1
Overall Success rate:
40%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Sanofi
Rasburicase
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use